Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director · President/CEO and Board Chair | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Bobak Azamian Living Trust established April 16, 2018 | 827,991 |
Last balance in matching sequence
After 2026-09-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-04 · Sale · Disposed 7,100 · Balance 830,891 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Row 2 · 2026-09-04 · Sale · Disposed 2,900 · Balance 827,991 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. |
| Common StockSEC Table I · non-derivative | Direct | 33,421 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 33,421 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 12, 2023 21:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,100 | $20.01 | $62,031.00 |
DisclosureSEC source: 0001209191-23-036433 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,040,006 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| May 17, 2023 Filed May 19, 2023 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $15.90 | $127,200.00 |
DisclosureSEC source: 0001827672-23-000031 · wf-form4_168453770654909.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,043,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.72 to $16.26. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| May 10, 2023 Filed May 12, 2023 21:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $16.80 | $151,200.00 |
DisclosureSEC source: 0001827672-23-000030 · wf-form4_168392571200364.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,051,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.37 to $17.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| May 01, 2023 Filed May 2, 2023 23:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,841 | $15.10 | $88,199.10 |
DisclosureSEC source: 0001827672-23-000028 · wf-form4_168306879822123.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,060,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| April 28, 2023 Filed May 2, 2023 23:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,278 | $15.13 | $64,726.14 |
DisclosureSEC source: 0001827672-23-000028 · wf-form4_168306879822123.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,065,947 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.26. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 21:22 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,311 | $15.03 | $34,734.33 |
DisclosureSEC source: 0001827672-23-000026 · wf-form4_168245771899403.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,070,225 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 21:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $13.60 | $108,800.00 |
DisclosureSEC source: 0001827672-23-000024 · wf-form4_168211375019028.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,072,536 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.13 to $14.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 737 | $12.15 | $8,954.55 |
DisclosureSEC source: 0001827672-23-000022 · wf-form4_167961543559554.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,597 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 709 | $12.64 | $8,961.76 |
DisclosureSEC source: 0001827672-23-000022 · wf-form4_167961543559554.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,334 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 679 | $12.89 | $8,752.31 |
DisclosureSEC source: 0001827672-23-000022 · wf-form4_167961543559554.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,043 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:01 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 741 | $12.61 | $9,344.01 |
DisclosureSEC source: 0001827672-23-000020 · wf-form4_167943965959717.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,722 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:01 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 795 | $13.28 | $10,557.60 |
DisclosureSEC source: 0001827672-23-000020 · wf-form4_167943965959717.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,463 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 791 | $13.43 | $10,623.13 |
DisclosureSEC source: 0001827672-23-000018 · wf-form4_167909053944482.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,258 F5 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholdingobligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 11,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-23-000018 · wf-form4_167909053944482.xml · derivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,898 Underlying: Common Stock · 11,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. F7 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 11,299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001827672-23-000018 · wf-form4_167909053944482.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F4 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $13.79 | $110,320.00 |
DisclosureSEC source: 0001827672-23-000018 · wf-form4_167909053944482.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,080,536 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.52 to $14.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:13 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 717 | $15.01 | $10,762.17 |
DisclosureSEC source: 0001827672-23-000016 · wf-form4_167848639670548.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,088,536 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 67,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017996 · doc4.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,900 Underlying: Common Stock · 67,900 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 100,242 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017996 · doc4.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,242 Underlying: Common Stock · 100,242 shares Expires 2033-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:13 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,853 | $15.02 | $72,892.06 |
DisclosureSEC source: 0001827672-23-000016 · wf-form4_167848639670548.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,089,253 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $15.28 | $122,240.00 |
DisclosureSEC source: 0001827672-23-000014 · wf-form4_167667087235492.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,094,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.03 to $15.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 21:54 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $15.14 | $136,260.00 |
DisclosureSEC source: 0001827672-23-000012 · wf-form4_167606603017023.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,102,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.03 to $15.53. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,856 | $15.45 | $75,025.20 |
DisclosureSEC source: 0001827672-23-000010 · wf-form4_167468692702601.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,111,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 20, 2023 Filed Jan 20, 2023 23:41 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 240 | $15.00 | $3,600.00 |
DisclosureSEC source: 0001827672-23-000006 · wf-form4_167425809399971.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,116,373 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 23:41 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $14.56 | $116,480.00 |
DisclosureSEC source: 0001827672-23-000006 · wf-form4_167425809399971.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,116,613 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $14.40 to $14.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 23:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,904 | $15.11 | $58,989.44 |
DisclosureSEC source: 0001827672-23-000004 · wf-form4_167365360777704.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,124,613 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 905 | $15.17 | $13,728.85 |
DisclosureSEC source: 0001827672-23-000002 · wf-form4_167348676340762.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,128,517 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 01:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 729 | $15.15 | $11,044.35 |
DisclosureSEC source: 0001827672-23-000002 · wf-form4_167348676340762.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,129,422 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.02 to $15.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| January 06, 2023 Filed Jan 24, 2023 23:13 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 411 | $15.00 | $6,165.00 |
DisclosureSEC source: 0001827672-23-000008 · wf-form4_167460198945770.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,129,740 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: This is an inadvertent late filing due to an administrative error. As a result of this administrative error, the shares sold on January 6, 2023 were erroneously included in the Table I, Column 5 totals of the Form 4s filed by the Reporting Person on January 11, 2023, January 13, 2023 and January 20, 2023. F4 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 23:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $14.57 | $116,560.00 |
DisclosureSEC source: 0001827672-22-000020 · wf-form4_167175011949009.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,130,151 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $14.37 to $14.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 23:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 535 | $15.01 | $8,030.35 |
DisclosureSEC source: 0001827672-22-000018 · wf-form4_167157931321935.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,138,151 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 21:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,420 | $15.08 | $96,813.60 |
DisclosureSEC source: 0001827672-22-000016 · wf-form4_167122749083590.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,138,686 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 745 | $17.31 | $12,895.95 |
DisclosureSEC source: 0001827672-22-000014 · wf-form4_166880576794208.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,145,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.24 to $17.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,255 | $16.81 | $121,956.55 |
DisclosureSEC source: 0001827672-22-000014 · wf-form4_166880576794208.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,145,851 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.24 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $17.87 | $160,830.00 |
DisclosureSEC source: 0001827672-22-000012 · wf-form4_166846112850981.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,153,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.49 to $18.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $17.60 | $1,760.00 |
DisclosureSEC source: 0001827672-22-000010 · wf-form4_166638381380111.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,162,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,900 | $16.91 | $133,589.00 |
DisclosureSEC source: 0001827672-22-000010 · wf-form4_166638381380111.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,162,206 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.51 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,821 | $16.24 | $45,813.04 |
DisclosureSEC source: 0001827672-22-000008 · wf-form4_166577950145627.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,170,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.21 to $16.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,179 | $15.76 | $97,381.04 |
DisclosureSEC source: 0001827672-22-000008 · wf-form4_166577950145627.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,172,927 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.14 to $16.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 22:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $17.05 | $1,704.50 |
DisclosureSEC source: 0001209191-22-051179 · doc4.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,179,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 22:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,900 | $16.30 | $128,770.00 |
DisclosureSEC source: 0001209191-22-051179 · doc4.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,179,206 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.96 to $16.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:28 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $16.01 | $144,090.00 |
DisclosureSEC source: 0001827672-22-000006 · wf-form4_166336012093561.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,187,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.51 to $16.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 736 | $17.44 | $12,835.84 |
DisclosureSEC source: 0001827672-22-000004 · wf-form4_166094216194304.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,196,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.22 to $17.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,264 | $16.50 | $119,856.00 |
DisclosureSEC source: 0001827672-22-000004 · wf-form4_166094216194304.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,196,842 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.11 to $16.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 45,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-22-000002 · wf-form4_164703352044513.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,197 Underlying: Common Stock · 45,197 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 154,067 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0001827672-22-000002 · wf-form4_164703352044513.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,067 Underlying: Common Stock · 154,067 shares Expires 2032-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 578 | $26.76 | $15,467.28 |
DisclosureSEC source: 0001819790-21-000057 · wf-form4_163857571118270.xml · nonDerivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,204,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F6 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.57 to $27.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 760 | $25.90 | $19,684.00 |
DisclosureSEC source: 0001819790-21-000057 · wf-form4_163857571118270.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,204,684 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F5 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.33 to $26.26. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,101 | $24.70 | $51,894.70 |
DisclosureSEC source: 0001819790-21-000057 · wf-form4_163857571118270.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,205,444 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.3 to $25.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,394 | $23.86 | $57,120.84 |
DisclosureSEC source: 0001819790-21-000057 · wf-form4_163857571118270.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,207,545 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $23.28 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.